Metformin has been associated with better survival in patients with breast cancer treated for diabetes, compared to other diabetic drugs [11, 12] although a phase III trial showed a lack of efficacy of metformin in preventing breast cancer recurrence in non-diabetic women except for the subgroup of HER-2 positive disease [13]. Here, ERBB2 is linked to breast cancer.